Diagnosis and Treatment

Diagnosis and Treatment accounts for 22% of scored questions on the ANCC PMHNP-BC exam. This domain covers diagnostic criteria application, differential diagnosis, evidence-based pharmacotherapy, treatment planning, and somatic therapies including ECT and TMS.

Expect questions on first-line medication selection for major psychiatric disorders, mechanisms of action, drug-drug interactions through the cytochrome P450 system, and monitoring requirements. The exam emphasizes practical prescribing decisions: when to augment vs. switch, how to manage treatment resistance, and which evidence-based algorithms to follow.

Treatment planning questions test your ability to develop comprehensive, individualized plans that integrate pharmacotherapy, psychotherapy referrals, level of care decisions, and patient education. You will need to know controlled substance regulations, black box warnings, and population-specific treatment modifications.

• ✕Confusing CYP450 inhibitors with inducers. Fluvoxamine is a potent CYP1A2 inhibitor, while carbamazepine is a CYP3A4 inducer. Mixing these up leads to wrong answers on drug interaction questions.
• ✕Not applying evidence-based treatment algorithms. Jumping to third-line treatments without trialing adequate doses and durations of first-line agents is a common exam trap.
• ✕Treating all SSRIs as interchangeable. The exam tests specific differences: paroxetine's anticholinergic load, fluoxetine's long half-life, fluvoxamine's unique CYP profile, and sertraline's relative safety in pregnancy.
• ✕Overlooking level of care decisions. Not all patients need inpatient admission, and not all can be safely managed outpatient. The exam tests your judgment about when to step up or step down the level of care.
• ✕Forgetting monitoring timelines. Lithium levels at 12 hours post-dose at steady state, clozapine ANC weekly for 6 months, and lamotrigine slow titration to reduce Stevens-Johnson risk.